Recent advances in the discovery and development of stilbenes and lactones in anticancer therapy

Bibliography

• PICMAN AK: Biological activities of sesquiterpene lactones. Biochein. Syst. Ecol (1986) 14:255–281.
   Web of Science ®Google Scholar
• INAYAT-HUSSAIN SH, OSMAN AB, DIN LB et al: Caspases-3 and -7 are activated in goniothalamin-induced apoptosis in human Jurkat T-cells. FEBS Letts. (1999) 456(3):379–383.
   PubMed Web of Science ®Google Scholar
• INAYAT-HUSSAIN SH, ANNUAR BO, DIN LB, TANIGUCHI N: Altholactone, a novel styryl-lactone induces apoptosis via oxidative stress in human HL-60 leukemia cells. Toxicol Letts. (2002) 131:153–159.
   PubMed Web of Science ®Google Scholar
• INAYAT-HUSSAIN SH, OSMAN AB, DIN LB, ALI AM, ROSS D: Loss of mitochondrial transmembrane potential and caspase-9 activation during apoptosis induced by the novel styryl-lactone goniothalamin in HL-60 leukemia cells. Toxicol In Vitro (2003) 17:433–439.
   PubMed Web of Science ®Google Scholar
• BERMEJO A, LEONCE S, CABEDO N et al.: Semisynthesis and cytotoxicity of styryl-lactone derivatives. J. Nat. Prod (1999) 62:1106–1109.
   PubMed Web of Science ®Google Scholar
• THOMAS NE LEE KC, PARAIDATHU T, WEBER JF, AWANG K: Manganese Triacetate oxidative lactonisation of electron rich stilbenes possessing catechol and resorcinol substitution (resveratrol analogues). Tetrahedron Letts (2002) 43:3151–3155.
   Web of Science ®Google Scholar
• SUZUKI K, YAHARA S, MAEHATA K, UYEDA M: Isoaurostatin, a novel topoisomerase inhibition produced by Thermonospora alba. j Nat. Prod. (2001) 64:204–207.
   PubMed Web of Science ®Google Scholar
• MANN J: Timeline: natural products in cancer chemotherapy: past, present and future. Nat. Rev Cancer (2002) 2:143–148.
   PubMed Web of Science ®Google Scholar
• ••Very good perspective on using naturalproducts in cancer chemotherapy
   Google Scholar
• NEWMAN DJ, CRAGG GM, SNADER KM: Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod (2003) 66(7):1022–1037.
   PubMed Web of Science ®Google Scholar
• HARVEY A: Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today(2000) 5(7):294–300.
   PubMed Web of Science ®Google Scholar
• STROHL WR: The role of natural products in a modern drug discovery program. Drug Discov. Today (2000) 5(2):39–41.
   PubMed Web of Science ®Google Scholar
• HART JH: Role of phytostilbenes in decayand disease resistance. Ann. Rev Phytopathol (1981) 19:437–458.
   Web of Science ®Google Scholar
• SOTHEESWARAN S, PASUPATHY V: Distribution of resveratrol oligomers in plants. Phytocheinistly (1993) 32:1083–1092.
   Web of Science ®Google Scholar
• BRUNETON J: Pharinacognosy phytocheinistry medicinal plants. Technique & Documentation-Lavoisier. Paris, France (1995).
   Google Scholar
• KYOUNG SE: Structure elucidation of bioactive constituents of two plants in the Dipterocarpaceae [abstract]. Disc. Abs hat. (1997) 58-07B:3575.
   Google Scholar
• WATERHOUSE AL, RAVENTOS LR: The occurrence of piceid, a stilbene glucoside, in grape berries. Phytocheinistry (1994) 37:571–573.
   Web of Science ®Google Scholar
• ROMERO-PEREZ Al, LAMUELARAVENTOS RM, WATERHOUSE AL, DELATORREBORONAT MC: Levels of cis- and trans-resveratrol and their glucosides in white and rose Vitis vinifera wines from Spain. J. Agric. Food Chem. (1996) 44:2124–2128.
   Web of Science ®Google Scholar
• GORHAM J: The Biochemistry of the Stilbenoids. Chapman & Hall, UK (1995).
   Google Scholar
• GUSMAN J, MALONNE H, ATASSI G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis (2001) 22(8):1111–1117.
   PubMed Web of Science ®Google Scholar
• •A review of the chemopreventive and chemotherapeutic activities of resveratrol.
   Google Scholar
• CLEMENT MV, HIRPARA JL, CHAWDURY SH, PERVAIS S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood (1998) 92(3):996–1002.
   PubMed Web of Science ®Google Scholar
• HOLMES-MCNARY M, BALDWIN AS JR: Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IlcB kinase. Cancer Res. (2000) 60(13):3477–3483.
   PubMed Web of Science ®Google Scholar
• JANG M, CAI L, UDEANI GO et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science (1997) 275:218–220.
   PubMed Web of Science ®Google Scholar
• Dong Z: Molecular mechanism of the chemopreventive effect of Resveratrol. Mutation Res (2003) 523–524:145–150.
   Google Scholar
• •Excellent review on the mechanisms of resveratrol.
   Google Scholar
• SHE QB, MA WY, WANG M, KAJI A, HO CT, DONG Z: Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved. Oncogene (2003) 22(14):2143–2150.
   PubMed Web of Science ®Google Scholar
• MACCARRONE M, LORENZON T, GUERRIERI P, AGRO AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eui: Biochem . (1999) 265(1):27–34.
   PubMedGoogle Scholar
• ENGLER TA, DRANEY BW, GFESSER GA: 1994. Evaluation of a synthetic route to E-viniferin based on a new method for the stereoselective preparation of 2,3-diary1-2,3-dihydrobenzofurans. Tetrahedron Lett. (1994) 35(11):1661–1664.
   Google Scholar
• LANGCAKE P, PRYCE RJ : The production of resveratrol by Vitis vinifera and other members of the vitaceae as a response to infection or injury. Physiol Plant Pathol (1977) 9:77–86.
   Google Scholar
• SOTHEESWARAN S, SULTANBAWA MUS, SURENDRAKUMAR 5: Polyphenols from dipterocarp species: vaticaffinol and E-viniferin. I Chem. Soc. Perkin Trans. (1985) 1(1):159–162.
   Google Scholar
• SULTANBAWA MUS, SURENDRAKUMAR S, BLADON P: Distichol, an antibacterial polyphenol from Shorea disticha. Phytochemistiy (1987) 26(3):799–801.
   Web of Science ®Google Scholar
• TANAKA T, ITO T, NAKAYA K, IINUMA M, RISWAN 5: Oligostilbenoids in stem bark of Vatica rassak Phytochemismy (2000) 54(1):63–69.
   Google Scholar
• TANAKA T, ITO T, IDO Y et al: Stilbenoids in the stem bark of Hopea parvillora. Phytochemismy (2000) 53(8):1015–1019.
   PubMed Web of Science ®Google Scholar
• OHYAMA M, TANAKA T, ITO T, IINUMA M, BASTOW KF, LEE KH: Cytotoxicity of naturally occurring resveratrol oligomers and their acetate derivatives. Bioorg. Med. Chem. Lett. (1999) 9:3057–3060.
   PubMed Web of Science ®Google Scholar
• MISHIMA S, MATSUMOTO K, FUTAMURA K et al.: Antitumor effect of stilbenoids from Vateria indica against allografted sarcoma S-180 in animal model. J. Exp. Ther. Onto] (2003) 3(5):283–288.
   PubMedGoogle Scholar
• AYRES DC, LOIKE JD: Lignans, chemical, biological and clinical properties. In: Chemistry and pharmacology of natural products. Cambridge University Press, Cambridge, UK (1990).
   Google Scholar
• WHITE JC, HINES LH, RATHMELL JP: Inhibition of 1-I3-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts. Cancer Res. (1985) 45(7):3070–3075.
   PubMed Web of Science ®Google Scholar
• LONG BH, MUSIAL ST, BRATTAIN MG: Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res. (1985) 45(7):3106–3112.
   PubMed Web of Science ®Google Scholar
• CHABNER BA, COLLINS JM: Cancer chemotherapy: principles and practice. JB Lippincott Press, Philadelphia (1990).
   Google Scholar
• MAANEN JM, RETEL J, VRIES J, PINEDO HM: Mechanism of action of antitumor drug etoposide: a review.' Nat. Cancer Inst. (1987) 80(19):1526–1533.
   Google Scholar
• EICH E, SCHULZ J, KALOGA M, MERZ H, SCHRODER HC, MULLER WE: Interference of epipodophyllotwdns and natural lignanolides with topoisomerase II: a proposed molecular mechanism. Planta Merl (1991) 57:A7–A8.
   Google Scholar
• ZHOU XM, LEE KJH, CHENG L et al: Antitumor agents. 144. New y-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase. .1. Med. Chem. (1994) 37:287–292.
   Google Scholar
• KUPCHAN SM, BRITTON RW, ZIEGLER MF, GILMORE CJ, RESTIVO RJ, BRYAN RF: Steganacin and steganangin, novel antileukemic lignan lactones from Steganataenia araliacea. .1. Am. Chem. Soc. (1973) 95:1335–1336.
   PubMed Web of Science ®Google Scholar
• WANG WJ, REBHUN LI, KUPCHAN SM: Antimitotic and antitubulin activity of the tumor inhibitor steganacin. Cancer Rev. (1977) 37:3071–3079.
   PubMed Web of Science ®Google Scholar
• MOUSAVI Y, ADLERCREUTZ H: Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. I Steroid Biochem. Ma Biol. (1992) 41(3-8):615–619.
   PubMed Web of Science ®Google Scholar
• ADLERCREUTZ H, BANNWART C, WAHALA K: Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. Steroid Biochem. Mol Biol. (1993) 44(2):147–153.
   PubMed Web of Science ®Google Scholar
• INGRAM D, SANDERS K, KOLYBABA M, LOPEZ D: Case-control study of phyto-oestrogens and breast cancer. Lancet (1997) 350(9083):990–994.
   PubMed Web of Science ®Google Scholar
• SUNG MK, LAUTENS M, THOMPSON LU: Mammalian lignans inhibit the growth of estrogen-independent human colon. Anti-Cancer Res. (1998) 18(3):1405–1408.
   PubMedGoogle Scholar
• MCDONIEL PB, COLE JR: Antitumoractivity of Bursera schlechtendalii (Burseraceae): isolation and structure determination of two new lignans. Pharm . ScL (1972) 61(12):1992–1994.
   PubMed Web of Science ®Google Scholar
• LEWIS MA, ARNASON JT, PHILOGENE BJR, RUPPRECHT JK, MCLAUGHLIN JL: Inhibition of respiration at site I by asimicin, an insecticidal acetogenin of the Pawpaw, Asimina miloba (Annonaceae). Pestic. Biochem. Physiol (1993) 45:15–23.
   Web of Science ®Google Scholar
• AHAMMADSAHIB KI, HOLLINGWORTH RM, MCGOVREN JP, HUI YH, MCLAUGHLIN JL: Mode of action of bullatacin: a potent antitumor and pesticidal Annonaceous acetogenin. Life Sci. (1993) 53:1113–1120.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-COLOMA A, GUADANO A, DE INES C, MARTINEZ-DIAZ R, CORTES D: Selective action of acetogenin mitochondrial complex I inhibitors. Z Naturforsch (2002) 57(11-12):1028–1034.
   Google Scholar
• ABE M, KENMOCHI A, ICHIMARU N, HAMADA T, NISHIOKA T, MIYOSHI H: Essential structural features of acetogenins: role of hydroxy groups adjacent to the bis-THF rings. Bioorg. Med. Chem. Lett. (2004) 14(3):779–782.
   PubMed Web of Science ®Google Scholar
• MORRE DJ, DECABO R, FARLEY C, OBERLIES N H, MCLAUGHLIN J L: Mode of action of bullatacin, a potent antitumor acetogenin: inhibition of NADH wddase activity of HeLa and HL-60, but not liver, plasma membranes. Life Sci. (1995) 56(5):343–348.
   PubMed Web of Science ®Google Scholar
• OBERLIES NH, CHANG CJ, MCLAUGHLIN JL: Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells. Med. Chem. (1997) 40(13):2102–2106.
   Web of Science ®Google Scholar
• HOPP DC, ZENG L, GU Z, MCLAUGHIN JL: Squamotacin: an annonaceous acetogenin with cytotoxic selectivity for the human prostate tumor cell line (PC-3). Nat. Prod. (1996) 59(2)97–99.
   Google Scholar
• ALALI FQ, LU Z, YAN Z, QING Y, HOPP DC, SCHWEDLER JT, MCLAUGHLIN JL: 4-Deoxyannomontacin and (2,4-cis and trans)-annomontacinone, new bioactive mono-tetrahydrofuran annonaceous acetogenins from Coniothalamus giganteus. Bioorg. Med. Chem. (1997) 5(3):549–555.
   PubMed Web of Science ®Google Scholar
• LIU X-X, ALALI F, HOPP DC, ROGERS LL, PILARINOU E, MCLAUHGLIN JL: Glabracins A and B, two new acetogenins from Annona glabra. Bioorg Med. Chem. (1998) 6 (7):959–965.
   PubMed Web of Science ®Google Scholar
• LIU X-X, ALALI FQ, PILARINOU E, MCLAUGHLIN JL: Two bioactive mono-tetrahydrofuran acetogenins, annoglacins A and B from Annona glabra. Phytochemistry (1999) 50 (5):815–821.
   PubMed Web of Science ®Google Scholar
• SAUSVILLE EA. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Cum Med. Chem. Anti-Cancer Agents. (2003) 3(1):47–56.
   PubMedGoogle Scholar
• ••A thorough review on recent CDKinhibitors.
   Google Scholar
• SOMEYA A, TANAKA N, OKUYAMA A: Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem. Biophys. Res. Commun. (1994) 198(2):536–545.
   PubMed Web of Science ®Google Scholar
• KITAGAWA M, HIGASHI H, TAKAHASHI IS et al.: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene (1994) 9(9):2549–2557.
   PubMed Web of Science ®Google Scholar
• HIDA D, NAKATA K, SHIMA Y et al: Suppression of albumin and a-fetoprotein gene expression by butyrolactone I, selective inhibitor of the cdk family, in HuH-7 human hepatoma cells. Anti-Cancer Res. (1998) 18:4317–4322.
   PubMed Web of Science ®Google Scholar
• TUCHINDA P, UDCHACHON J, REUTRAKUL V, SANTISUK T et al.: Bioactive butenolides from Melodomm fruticosum. Phytochemismy (1991) 30(8):2685–2689.
   Web of Science ®Google Scholar
• ROBBERS JE, SPEEDIE MK, TYLER VE: Pharmacognosy and pharmacobiotechnology. Williams & Wilkins Press, Baltimore (1996):79–90.
   Google Scholar
• LEE AL, HUANG ES, PIANTADOSI C, PAGANO JS, GEISSMAN TA: Cytotoxicity of sesquiterpene lactones. Cancer Res. (1971) 31:1649–1654.
   PubMed Web of Science ®Google Scholar
• MECK R, PIANTADOSI C, HUANG ES: Antitumor agents: Cytotoxicity and in vivo activity of helenalin esters and related derivatives. Med. Chem. (1973) 16(3):299–301.
   Web of Science ®Google Scholar
• ROSOWKSKY L, PAPATHANASOPOULOS N, LAZARUS H, FOLEY GE, MODEST EJ: Cysteine scavengers 2: Synthetic y-methylenebutyrolactones as potential tumor inhibitors. Med. Chem. (1974) 17(7):672–676.
   Web of Science ®Google Scholar
• KUPCHAN SM, FESSLER DC, EAKIN MA, GIACOBBE TJ : Reaction of alpha methylene lactone tumor inhibitors with model biological nucleophiles. Science (1970) 168:376–378.
   PubMed Web of Science ®Google Scholar
• PARK L, NAKAGAWA M, HIROTA A, NAKAYAMA M: Methylenolactocin, a novel antitumor antibiotic from Penicillium sp. I Antibiotics (1998) 41(6):751–758.
   Google Scholar
• KUHAJDA FP, PIZER ES, LI JN, MANI NS, FREHYWOT GL, TOWNSEND CA: Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Nati Acad. Sci. USA (2000) 97:3450–3454.
   PubMed Web of Science ®Google Scholar
• PIZER ES, THUPARI J, HAN WF et al.: Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. (2000) 60:213–218.
   PubMed Web of Science ®Google Scholar
• ZHOU XM, LEE KJH, CHENG L et aL:Antitumor agents. 144. New y-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase. Med . Chem. (1994) 37:287–292.
   Google Scholar
• JONSSON E, DHAR S, JONSSON B, NYGREN P, GRAF W, LARSSON R: Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eut: Cancer(2000) 36(16):2120–2127.
   PubMed Web of Science ®Google Scholar
• KURTZ JE, ANDRES E, NATARAJAN-AME S, NOEL E, DUFOUR P: Oral chemotherapy in colorectal cancer treatment: review of the literature. Eut: Intern. Med. (2003)14(1):18–25.
   PubMedGoogle Scholar
• GRIGGS J, METCALFE JC, HESKETH R: Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. (2001) 2:882–887.
   Web of Science ®Google Scholar
• LIN CM, SINGH SB, CHU PS et al.: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. (1988) 34(2):200–208.
   PubMed Web of Science ®Google Scholar
• LIQ, SHAM HL: Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. Expert Opin. Thec Patents (2002) 12(11):1663–1702.
   Web of Science ®Google Scholar
• ROSS D, KEPA JK, WINSKI SL, BEALL HD, ANWAR A, SIEGEL D: NAD(P)H:quinone coddoreductase 1 (NQ01): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. (2000) 129(1-2):77–97.
   PubMed Web of Science ®Google Scholar
• SMITH KA, HILL SA, BEGG AC, DENEKAMP J: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br. J. Cancer (1988) 57:247–253.
   PubMed Web of Science ®Google Scholar
• GUENGERICH P, CHUNY-J, KIM D, GILLAM EMJ, SHIMADA T:Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutation Res./Fund. Mol. Mech. Mut. (2003) 523–524:173–182.
   Google Scholar
• KIM S, KO H, PARK JE, JUNG S, LEE SK, CHUN YJ : Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.' Med. Chem. (2002) 45(1):160–164.
   Google Scholar
• CHANG TT, CHOU TC: Rational approach to the clinical protocol design for drug combinations: a review. Acta. Paediam. Taiwan (2000) 41(6):294–302.
   PubMedGoogle Scholar
• CARMELIAT P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407:249–257.
   PubMed Web of Science ®Google Scholar
• DANCEY JE: Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. (2002) 16(5):1101–1114.
   PubMed Web of Science ®Google Scholar
• ••Very good review article about CC1–779.
   Google Scholar
• BORK PM, SCHMITZ ML, KUHNT M, ESCHER C, HEINRICH M: Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-icB. FEBS Lett. (1997) 402(1):85–90.
   PubMed Web of Science ®Google Scholar
• HEHNER SP, HOFMANN TG, DROGE W, SCHMITZ ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-icB by targeting the IicB kinase complex. j branunol. (1999) 163:5617–5623.
   Google Scholar
• WEN J, YOU KR, LEE SY, SONG CH, KIM DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. Biol. Chem. (2002) 277(41):38954–38964.
   Google Scholar
• HUANG S, HOUGHTON PJ: Targeting mTOR signaling for cancer therapy. Cup: Opin. Phannacol. (2003) 3(4):371–377.
   PubMed Web of Science ®Google Scholar